(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Maarten J. van der Doelen discussing re-treatment of metastatic castration-resistant ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Danny Cortes discussing radiographic criteria to assess response to radioligand therapy. Currently, theranostics ...

This is a retrospective, observational, multicenter, longitudinal follow-up study to describe the treatment patterns received by the Spanish patients who received darolutamide in the ARAMIS study, ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Miguel Muniz discussing the utility of post-treatment SPECT/CT for identifying disease ...

Metastatic papillary renal cancer has poor outcomes, and new treatments are needed. There is a strong rationale for investigating the combination of mesenchymal epithelial transition receptor (MET) ...